“Rising Incidence of Uveal Melanoma and Advancements in Cancer Immunotherapy”
- Uveal melanoma is the most common primary intraocular malignancy in adults, with increasing incidence noted in regions such as North America and Europe
- The rising awareness about ocular health, advancements in diagnostic technologies (e.g., OCT, angiography), and early detection campaigns are improving diagnosis rates of eye cancers
- Parallelly, breakthroughs in cancer immunotherapy have led to the development of novel drug classes, expanding treatment options for patients with rare cancers like eye melanoma
For instance,
- According to the American Cancer Society (2024), although uveal melanoma is rare, it accounts for over 85% of all eye melanomas, with approximately 2,000–2,500 new cases annually in the U.S. Improved survival and treatment rates are contributing to rising drug demand
- These developments are propelling the market for eye melanoma drugs, as more patients gain access to personalized, effective treatments
